| Lyuda Lundeen, ARNP | |
|
2824 Mahan Dr Ste 1, Tallahassee, FL 32308-5429 | |
| (850) 558-1260 | |
| (850) 558-1298 |
| Full Name | Lyuda Lundeen |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 13 Years |
| Location | 2824 Mahan Dr Ste 1, Tallahassee, Florida |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033481080 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LA2200X | Nurse Practitioner - Adult Health | 9322977 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tallahassee Neurological Clinic | 9032015946 | 35 |
News Archive
Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa.
EntreMed, Inc. has announced that it has initiated a Phase 1 study of ENMD-2076 in refractory multiple myeloma patients.
The American Society of Anesthesiologists (ASA) today joins Americans across the nation to recognize Doctors' Day 2012, an observance to celebrate the contributions of physicians.
Many human tumors express indoleamine 2,3-dioxygenase (IDO), an enzyme which mediates an immune-escape in several cancer types. Researchers in the Molecular Modeling group at the SIB Swiss Institute of Bioinformatics and Dr. Beno-t J. Van den Eynde's group at the Ludwig Institute for Cancer Research Ltd (LICR) Brussels Branch developed an approach for creating new IDO inhibitors by computer-assisted structure-based drug design. The study was presented in the January 2010 online issue of the Journal of Medicinal Chemistry.
With the growing awareness of ultraviolet exposure resulting in an increased risk of photoaging and skin cancers, consumers are using higher sun protection factor sunscreens with frequent reapplication.
› Verified 7 days ago
| Entity Name | Tallahassee Neurological Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982660569 PECOS PAC ID: 9032015946 Enrollment ID: O20031211000061 |
News Archive
Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa.
EntreMed, Inc. has announced that it has initiated a Phase 1 study of ENMD-2076 in refractory multiple myeloma patients.
The American Society of Anesthesiologists (ASA) today joins Americans across the nation to recognize Doctors' Day 2012, an observance to celebrate the contributions of physicians.
Many human tumors express indoleamine 2,3-dioxygenase (IDO), an enzyme which mediates an immune-escape in several cancer types. Researchers in the Molecular Modeling group at the SIB Swiss Institute of Bioinformatics and Dr. Beno-t J. Van den Eynde's group at the Ludwig Institute for Cancer Research Ltd (LICR) Brussels Branch developed an approach for creating new IDO inhibitors by computer-assisted structure-based drug design. The study was presented in the January 2010 online issue of the Journal of Medicinal Chemistry.
With the growing awareness of ultraviolet exposure resulting in an increased risk of photoaging and skin cancers, consumers are using higher sun protection factor sunscreens with frequent reapplication.
› Verified 7 days ago
| Entity Name | Tallahassee Memorial Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194774968 PECOS PAC ID: 6103724778 Enrollment ID: O20041029000600 |
News Archive
Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa.
EntreMed, Inc. has announced that it has initiated a Phase 1 study of ENMD-2076 in refractory multiple myeloma patients.
The American Society of Anesthesiologists (ASA) today joins Americans across the nation to recognize Doctors' Day 2012, an observance to celebrate the contributions of physicians.
Many human tumors express indoleamine 2,3-dioxygenase (IDO), an enzyme which mediates an immune-escape in several cancer types. Researchers in the Molecular Modeling group at the SIB Swiss Institute of Bioinformatics and Dr. Beno-t J. Van den Eynde's group at the Ludwig Institute for Cancer Research Ltd (LICR) Brussels Branch developed an approach for creating new IDO inhibitors by computer-assisted structure-based drug design. The study was presented in the January 2010 online issue of the Journal of Medicinal Chemistry.
With the growing awareness of ultraviolet exposure resulting in an increased risk of photoaging and skin cancers, consumers are using higher sun protection factor sunscreens with frequent reapplication.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lyuda Lundeen, ARNP 2824 Mahan Dr Ste 1, Tallahassee, FL 32308-5429 Ph: () - | Lyuda Lundeen, ARNP 2824 Mahan Dr Ste 1, Tallahassee, FL 32308-5429 Ph: (850) 558-1260 |
News Archive
Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial evaluating denosumab versus Zometa(R) (zoledronic acid) in the treatment of bone metastases in 2,046 patients with advanced breast cancer that met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa.
EntreMed, Inc. has announced that it has initiated a Phase 1 study of ENMD-2076 in refractory multiple myeloma patients.
The American Society of Anesthesiologists (ASA) today joins Americans across the nation to recognize Doctors' Day 2012, an observance to celebrate the contributions of physicians.
Many human tumors express indoleamine 2,3-dioxygenase (IDO), an enzyme which mediates an immune-escape in several cancer types. Researchers in the Molecular Modeling group at the SIB Swiss Institute of Bioinformatics and Dr. Beno-t J. Van den Eynde's group at the Ludwig Institute for Cancer Research Ltd (LICR) Brussels Branch developed an approach for creating new IDO inhibitors by computer-assisted structure-based drug design. The study was presented in the January 2010 online issue of the Journal of Medicinal Chemistry.
With the growing awareness of ultraviolet exposure resulting in an increased risk of photoaging and skin cancers, consumers are using higher sun protection factor sunscreens with frequent reapplication.
› Verified 7 days ago
Faye Darby Tinson, CNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1720 S Gadsden St, Tallahassee, FL 32301 Phone: 850-576-4073 Fax: 850-576-4073 | |
Janine Jones, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1607 Saint James Ct, Tallahassee, FL 32308 Phone: 850-878-8714 | |
Kelly Berlinghoff, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2610 W Tennessee St, Tallahassee, FL 32304 Phone: 850-765-4955 Fax: 850-807-2534 | |
Mrs. Romanise Mcswain, BSN, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2009 Miccosukee Rd Ste A, Tallahassee, FL 32308 Phone: 850-942-2299 | |
Mrs. Shara Bryant, DNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 1401 Centerville Rd Ste 300, Tallahassee, FL 32308 Phone: 850-877-5115 | |
Jennifer Oetting, APRN Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2406 E Plaza Dr, Tallahassee, FL 32308 Phone: 850-878-5322 | |
Rachel Oliver, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 2400 Miccosukee Rd, Tallahassee, FL 32308 Phone: 850-877-2105 |